The II National Congress of the “Italian Craniomandibular dysfunction Study Group”, which took place on 3rd and 4th June in Marina di Carrara, was also attended by ASAlaser in order to promote the Mphi D 5 device. Held at the CarraraFiere Congress Centre, the event entitled “Let’s chew on bruxism, mastichiamo il Bruxismo”, saw the exhibition of 19 posters, half of which represented works published in international magazines, and was attended by numerous delegates from many foreign countries. In addition, there was also an exceptional scientific program with speakers available to discuss various topics interactively with the public. Among the speakers there was also clinical researcher Dr Daniele Manfredini, Professor of Implantology and Craniomandibular Pathophysiology and Gnathology of the Masticatory system – Bruxism at the CLSOPD of the university of Padova, who presented a poster of the scientific study entitled “Comparison between three treatment modalities for the management of myofascial pain of jaw muscles: preliminary data from a randomized controlled trial” in which he uses MLS® Laser Therapy to treat some temporomandibular disorders.
“Our study – points out Professor Manfredini at the end of the Congress- rightly suggests how MLS® Laser Therapy could be considered a useful tool to manage the symptoms of overload on masticatory muscles and the temporomandibular articulation. Today’s challenge in the field of pain therapy is to find the key in order to favour a remission of the symptoms as quickly as possible and which is executed with reversible means and conservative therapies. “In this light, the results of my research confirm that MLS® Laser Therapy can find a worthy place within the field of issues of the stomatognathic system, as its overlapping efficiency in respect of the two principal treatment modes currently in use, (occlusal plates and cognitive behavioural therapy), makes this definitely promising and worthy of further research. Besides – ends Manfredini - the possibility that the Laser Therapy cycles may be carried out with closely spaced regular multiple sessions can definitely contribute to reinforce the efficiency of the above mentioned therapies”.
L'accesso alla visualizzazione dei prodotti e al materiale informativo è riservato agli operatori del settore in ottemperanza alla legislazione vigente. ASA richiede di qualificarsi come operatore del settore per procedere con la navigazione.
Decreto Legislativo 24 febbraio 1997, n°46 Articolo 21
1. E' vietata la pubblicità verso il pubblico dei dispositivi che, secondo disposizioni adottate con decreto del Ministro della Sanità, possono essere venduti soltanto su prescrizione medica o essere impiegati eventualmente con l'assistenza di un medico o di altro professionista sanitario.
2. La pubblicità presso il pubblico dei dispositivi diversi da quelli di cui al comma 1 è soggetta ad autorizzazione del Ministero della Sanità. Sulle domande di autorizzazione esprime parere la Commissione di esperti prevista dall'articolo 6, comma 3, del decreto legislativo
30 dicembre 1992, n. 541, che a tal fine è integrata da un rappresentante del Dipartimento del Ministero della Sanità competente in materia di dispositivi medici e da uno del Ministero dell'Industria, del commercio e dell'artigianato.
Some of the contents of this website cannot be disclosed in the USA and its territories and possesions, for regulatory reasons. If you are a US resident, please click on the button here below and access ASA's distributor website for North America.